Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.canagen.com
Number of Employees: -
Year Founded: 1997
Total Amount Raised (CAD mm)†: 0.75
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Canagen Pharmaceuticals Inc. manufactures and markets dosage generic pharmaceuticals, over-the counter (OTC) medication, and active pharmaceutical ingredients (APIs). The company offers generic drugs; and cephalosporin, carbapenem, fluoroquinolone, penicillin, tetracyclinem, GI, beta blocker, anti-asthma, anti-histamine, anti-viral, dermatological, angiotensin-converting enzyme (ACE) inhibitors, cholesterol reducer, macrolide, angiotensin II receptor blocker, CNS, analgesic, anti-diabetic, urology, and others active pharmaceutical ingredients. It also offers seal and fish oil, milk thistle, EPO, flax seed oil, saw palmetle, glucosamine sulphate, lecithin, shark liver oil, bee propolis, grape seed extract, ginkgo biloba, spirulina, and other OTC drugs and medicines; and polyvitamin drops for children, anti-viral spray for influenza and colds, and spirulina powder, as well as FerroHeme, a hemoglobin iron protein complex. Canagen Pharmaceuticals Inc. was formerly known as Sino Pharmaceuticals Corporation and changed its name to Canagen Pharmaceuticals Inc. in July 2011. The company was founded in 1997 and is based in Richmond, Canada. It has additional offices in Puttaparthi, India; Kwai Chung, Hong Kong; Larnaca, Cyprus; and Xi'an, China. Canagen Pharmaceuticals Inc. operates as a subsidiary of Fazio Group of Companies.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Aziz, Mahmoud S.
President & CEO


Primary Industry Classification
Pharmaceuticals


Primary Office Location
Building 152 11782 River Road | Richmond, BC | V6X 1Z7 | Canada
Phone: 604 303 9180   Fax: 604 303 9170

Parent Company
Fazio Group of Companies


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Global distribution, sales and marketing rights and interest for Flu-X®

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-24-2020
-
Merger/Acquisition
Seller
Global distribution, sales and marketing rights and interest for Flu-X®
Genix Pharmaceuticals Corporation (TSXV:GENX)
Canagen Pharmaceuticals Inc.
0.07
Oct-18-2012
Sep-5-2013
Merger/Acquisition
Seller
Canagen Pharmaceuticals Inc., FerroHem and Concomitant Global Sales and Marketing Rights
ALDA Pharmaceuticals Corp. (nka:Avricore Health Inc. (TSXV:AVCR))
Canagen Pharmaceuticals Inc.
0.29
Jun-18-2012
Sep-17-2012
Merger/Acquisition
Seller
Canagen Pharmaceuticals Inc., Pedia-Safe Polyvitamin Drops
ALDA Pharmaceuticals Corp. (nka:Avricore Health Inc. (TSXV:AVCR))
Canagen Pharmaceuticals Inc.
0.25
Apr-21-2009
-
Private Placement
Target
Sino Pharmaceuticals Corporation (nka:Canagen Pharmaceuticals Inc.)


0.73
Apr-21-2009
Cancelled
Merger/Acquisition
Buyer
Portia Exploration Ltd.
Sino Pharmaceuticals Corporation (nka:Canagen Pharmaceuticals Inc.)

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-24-2020
M&A Transaction Announcements
Genix Pharmaceuticals Corporation (TSXV:GENX) entered into an agreement to acquire Global distribution, sales and marketing rights and interest for Flu-X® from Canagen Pharmaceuticals Inc. for CAD 0.1 million.
Mar-27-2020
Client Announcements
Genix Pharmaceuticals Corporation Enters into an Exclusive Global Distribution Agreement with Canagen Pharmaceuticals Inc
Jan-14-2020
Client Announcements
Genix Pharmaceuticals Corp. Enters into an Acquisition Agreement with Canagen Pharmaceuticals to Purchase Sole and Exclusive Distribution, Sales and Marketing Rights and Interest for Canada
Jul-19-2017
Lawsuits & Legal Issues
VANC Pharmaceuticals Inc. Files a Notice of Civil Claim in the Supreme Court of British Columbia Against Canagen Pharmaceuticals Inc
Sep-05-2013
M&A Transaction Closings
Nuva Pharmaceuticals Inc. (TSXV:NPH) completed the acquisition of FerroHem and concomitant global sales and marketing rights from Canagen Pharmaceuticals Inc. for CAD 0.29 million.


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-18-2012
-
Canagen Pharmaceuticals Inc.
SEDAR
News Releases
32 KB
Feb-15-2002
-
Canagen Pharmaceuticals Inc.
SEC
SB-2
208 KB
Jan-30-2002
Jan-28-2002
Canagen Pharmaceuticals Inc.
SEC
8-K (1, 2, 5, 7)
332 KB
Dec-06-2001
Dec-06-2001
Canagen Pharmaceuticals Inc.
SEC
DEF 14C
278 KB
Nov-26-2001
Sep-30-2001
Canagen Pharmaceuticals Inc.
SEC
10KSB
43 KB
Nov-23-2001
Nov-21-2001
Canagen Pharmaceuticals Inc.
SEC
PRE 14C
277 KB
Jul-19-2001
Jun-30-2001
Canagen Pharmaceuticals Inc.
SEC
10QSB
22 KB
Jul-19-2001
Mar-31-2001
Canagen Pharmaceuticals Inc.
SEC
10QSB
22 KB
Feb-20-2001
Sep-30-2000
Canagen Pharmaceuticals Inc.
SEC
10KSB
44 KB
Feb-14-2001
Dec-31-2000
Canagen Pharmaceuticals Inc.
SEC
10QSB
21 KB

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Aziz, Mahmoud S.
President & CEO
604 303 9180
604 303 9170
maziz@sinopharmaceuticals.com
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
